Aggiornamento sulle tossicità dermatologiche degli inibitori di checkpoint immunitari.

The use of immune checkpoint inhibitors (ICIs) has emerged as a transformative approach in the treatment of various malignancies. ICIs target immune regulatory pathways-specifically cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1)-to reinvigorate anti-tumor immune responses. However, these therapies can induce immune-related adverse events (irAEs) due to systemic immune activation and loss of tolerance. Among the most common irAEs are those affecting the skin, manifesting as a spectrum of cutaneous autoimmune reactions. These range from self-limiting reactions (i.e. eczema-like reactions, psoriasis, lichenoid reactions, vi